A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 29, 2017

Study Completion Date

April 24, 2018

Conditions
Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
Interventions
DRUG

lipegfilgrastim

6 mg

DRUG

pegfilgrastim

6 mg

Trial Locations (60)

10117

Teva Investigational Site 32267, Berlin

10126

Teva Investigational Site 30062, Torino

10707

Teva Investigational Site 32277, Berlin

15236

Teva Investigational Site 32308, Frankfurt (Oder)

20162

Teva Investigational Site 30059, Milan

21680

Teva Investigational Site 32300, Stade

22081

Teva Investigational Site 32272, Hamburg

24116

Teva Investigational Site 32280, Kiel

26121

Teva Investigational Site 32274, Oldenburg

26603

Teva Investigational Site 32284, Aurich

26789

Teva Investigational Site 32311, Leer

27356

Teva Investigational Site 32291, Rotenburg (Wümme)

28006

Teva Investigational Site 31071, Madrid

28222

Teva Investigational Site 31070, Madrid

33332

Teva Investigational Site 32296, Gütersloh

34119

Teva Investigational Site 32310, Kassel

36043

Teva Investigational Site 32322, Fulda

38642

Teva Investigational Site 32273, Goslar

44623

Teva Investigational Site 32270, Herne

44625

Teva Investigational Site 32401, Herne

44791

Teva Investigational Site 32292, Bochum

45468

Teva Investigational Site 32281, Mülheim

46010

Teva Investigational Site 31073, Valencia

46026

Teva Investigational Site 31072, Valencia

46236

Teva Investigational Site 32294, Bottrop

47805

Teva Investigational Site 32309, Krefeld

50226

Teva Investigational Site 32276, Frechen

50674

Teva Investigational Site 32275, Cologne

52222

Teva Investigational Site 32288, Stolberg

53105

Teva Investigational Site 32400, Bonn

53113

Teva Investigational Site 32318, Bonn

63225

Teva Investigational Site 32289, Langen

65812

Teva Investigational Site 32314, Bad Soden am Taunus

65929

Teva Investigational Site 32302, Frankfurt-Hochst

66822

Teva Investigational Site 32313, Lebach

67655

Teva Investigational Site 32297, Kaiserslautern

70174

Teva Investigational Site 32268, Stuttgart

70376

Teva Investigational Site 32321, Stuttgart

74078

Teva Investigational Site 32295, Heilbronn

77933

Teva Investigational Site 32287, Lahr

78052

Teva Investigational Site 32266, Villingen-Schwenningen

Teva Investigational Site 32317, Villingen-Schwenningen

78224

Teva Investigational Site 32315, Singen

79106

Teva Investigational Site 32293, Freiburg im Breisgau

79110

Teva Investigational Site 32290, Freiburg im Breisgau

80131

Teva Investigational Site 30063, Napoli

86100

Teva Investigational Site 30061, Campobasso

88212

Teva Investigational Site 32304, Ravensburg

90766

Teva Investigational Site 32320, Fürth

92637

Teva Investigational Site 32286, Weiden

95028

Teva Investigational Site 32279, Hof

01127

Teva Investigational Site 32282, Dresden

01307

Teva Investigational Site 32269, Dresden

Teva Investigational Site 32303, Dresden

06110

Teva Investigational Site 32319, Halle

04103

Teva Investigational Site 32278, Leipzig

D-81377

Teva Investigational Site 32301, München

07381

Teva Investigational Site 32306, Pößneck

04860

Teva Investigational Site 32305, Torgau

08003

Teva Investigational Site 31074, Barcelona

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02044276 - A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia | Biotech Hunter | Biotech Hunter